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MicroRNAs (miRNAs) are a class of 20–24 nt non-coding RNAs that regulate gene expression primarily through post-
transcriptional repression or mRNA degradation in a sequence-specific manner. The roles of miRNAs are just beginning to be
understood, but the study of miRNA function has been limited by poor understanding of the general principles of gene
regulation by miRNAs. Here we used CNE cells from a human nasopharyngeal carcinoma cell line as a cellular system to
investigate miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia, and to explore the principles of
gene regulation by miRNAs. Through computational analysis, 96 miRNAs were predicted as putative regulators of VEGF. But
when we analyzed the miRNA expression profile of CNE and four other VEGF-expressing cell lines, we found that only some of
these miRNAs could be involved in VEGF regulation, and that VEGF may be regulated by different miRNAs that were
differentially chosen from 96 putative regulatory miRNAs of VEGF in different cells. Some of these miRNAs also co-regulate
other angiogenic factors (differential regulation and co-regulation principle). We also found that VEGF was regulated by
multiple miRNAs using different combinations, including both coordinate and competitive interactions. The coordinate
principle states that miRNAs with independent binding sites in a gene can produce coordinate action to increase the repressive
effect of miRNAs on this gene. By contrast, the competitive principle states when multiple miRNAs compete with each other for
a common binding site, or when a functional miRNA competes with a false positive miRNA for the same binding site, the
repressive effects of miRNAs may be decreased. Through the competitive principle, false positive miRNAs, which cannot
directly repress gene expression, can sometimes play a role in miRNA-mediated gene regulation. The competitive principle,
differential regulation, multi-miRNA binding sites, and false positive miRNAs might be useful strategies in the avoidance of
unwanted cross-action among genes targeted by miRNAs with multiple targets.
Citation: Hua Z, Lv Q, Ye W, Wong C-KA, Cai G, et al (2006) MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia. PLoS
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INTRODUCTION
MicroRNAs (miRNAs) were discovered over a decade ago but
only in recent years have they been recognized as one of the major
regulatory gene families in cells. As a new family of small non-
coding RNA molecules with approximately 22 nucleotides,
miRNAs regulate gene expression through translational repression
or mRNA degradation in a sequence-specific manner [1–4]. They
are known to be involved in gene functioning during development,
cell proliferation, apoptosis, differentiation, and carcinogenesis [5–
11]. MiRNA functional identification has become one of the most
active research fields in biology.
However, the study on miRNA function has been limited by
several obstacles. In addition to the difficulty of accurately
predicting their targets and validating these findings, poor
understanding of the general principles of gene regulation by
miRNAs is a major obstacle. Recently, with the development of
new computational algorithms, more and more targets regulated
by miRNAs have been predicted [12–19]. Along with the
accumulation of the knowledge about miRNAs, the complexity
of miRNA-mediated gene regulation is gradually emerging.
Discovery of the principles of gene regulation by miRNAs would
be helpful in the understanding of their highly complex
interactions, and in turn, their biological significance.
Some general principles of gene regulation mediated by
miRNAs have been predicted by a bioinformatics approach as
follows: (1) miRNAs appear to act cooperatively through multiple
target sites in one gene by either one or several different miRNAs,
and (2) most miRNAs are involved in translational regulation
through targeting several genes [15,20,21]. However, these
principles have yet to be validated. Furthermore, many questions
need to be addressed to better understand miRNA-mediated gene
regulation, including whether there is competitive action, the
opposite of coordinate action, among miRNAs; whether miRNA
co-targeted genes can be in functionally related gene groups;
whether miRNAs targeting multiple genes could cause unwanted
cross-reactions among functionally unrelated genes, and if so, how
to avoid these unwanted cross-reactions.
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e116Since angiogenesis is crucial for a wide variety of physiological
and pathological processes including development, wound healing,
inflammation, and tumor formation, the regulation of angiogenesis
is complex and well controlled. Many molecules have been
implicated as positive regulators of angiogenesis. Among them,
vascular endothelial growth factor (VEGF) is a pivotal angiogenic
factor. Its expression is regulated by many factors [22,23] but it is
not clear whether miRNA is involved in VEGF regulation under
hypoxia. In this study, we used human CNE cells (from nasophary-
ngeal carcinoma) as a model to investigate miRNA-directed
regulation of VEGF and other angiogenic factors under hypoxia,
and to explore the principles of gene regulation by miRNAs.
RESULTS
Computational predictions of putative miRNA
regulators of VEGF
To investigate whether miRNA is involved in VEGF regulation,
we first analyzed miRNA target sites or binding sites in the 39-
untranslated region (39-UTR) of VEGF and its cognate miRNAs
with a bioinformatics approach. Prediction of animal miRNA
targets is challenging because there is only a partial pairing of
miRNAs with their targets, and the mechanism of miRNA-
mediated regulation is poorly understood. To improve the
accuracy of binding site prediction, we used three target prediction
algorithms, miRanda software [12], RNAhybrid [19], and
FindTar, a bioinformatics approach designed in our lab. MiRNAs
with binding sites in the VEGF 39-UTR as predicted by two of the
three bioinformatics algorithms were selected as putative regula-
tors of VEGF. In total, 109 binding sites for miRNAs and 96 of
their cognate miRNAs were predicted (Table S1). A map of
miRNA binding to VEGF 39-UTR was generated and 2 binding
site-condense regions (MBSCR) were observed, including nt160–
195 and nt820–860 (Fig. 1A).
In nt160–195 MBSCR, we found a special miRNA binding site
at nt160–185, which is shared by 12 miRNAs (Fig. 1B). These
miRNAs belong to 4 miRNA clusters (Fig. 1C) and the sequences
of the seed region in the binding sites on the VEGF 39-UTR are
highly conserved across all mammals (Fig. 1D). We used
RNAcofold (http://www.tbi.univie.ac.at/,ivo/RNA/) [24] to
analyze the secondary structure of the multi-miRNA binding site
and its flank regions in the VEGF 39-UTR and found that the
binding sites were located in ‘unstable’ regions with multi-
branching loops (Fig. 1E), characteristic of an important miRNA
target site. Although it is common for one mRNA to have multi-
miRNA binding sites, the results of the computational prediction
still surprised us when so many miRNA binding sites and their
cognate miRNAs were found targeting VEGF. We then decided to
use CNE cells as a cellular system to investigate how miRNAs
regulate VEGF expression.
miRNA and VEGF Expression in CNE cells
Total RNA was obtained for miRNA chip analysis from CNE cells
both with and without hypoxia induction. The expression profile
of microRNAs in CNE cells is provided as supplementary data
(Fig. S1). We compared the expression of miRNAs between the
two samples and identified 13 miRNAs that were sharply down-
regulated and 6 miRNAs that were greatly up-regulated according
to microarray analysis, with fold change$3 (SAM version 2.1,
http://www-stat.stanford.edu/,tibs/SAM/index.html) [25,26].
Another 35 miRNAs were also detected in this cellular system,
but they did not appear to be differentially expressed between
these two samples (Tables 1, 2 and 3). Among these 54 miRNAs,
miR-16, miR-20a, miR-20b, let-7b, miR-17-5p, miR-27a, miR-106a,
miR-106b, miR-107, miR-193a, miR-210, miR-320, and miR-361
were predicted to target VEGF. MiR-15b was also predicted as
a putative miRNA regulator of VEGF by one computational
algorithm (FindTar).
As hypoxia is a strong inducer of VEGF, treatment with
DFOM, a hypoxia inducer, usually increases VEGF expression
[27]. We performed RT-PCR and ELISA assays to determine
VEGF expression at the mRNA and protein levels, and found that
VEGF was up-regulated in hypoxia-induced CNE cells compared
with control cells (Fig. 2A and B). These results were in sharp
contrast to the down-regulation of 13 different miRNAs. We
hypothesized that some of the miRNAs which were down-
regulated in hypoxia-induced CNE cells might unblock VEGF and
cause the increase in its expression. In line with this hypothesis, 4
of these 13 down-regulated miRNAs identified by miRNA chip
assays were predicted to target VEGF. These are miR-15b, miR-16,
miR-20a, and miR-20b. Down-regulation of these 4 miRNAs in
hypoxia-induced CNE cells was confirmed by an miRNA-
detecting experiment (Fig. 2C).
Validation of the repressive effect of miRNA
regulators on VEGF expression
To investigate the putative effects of miR-15b, miR-16, miR-20a,
and miR-20b, we determined the consequence of over-expressing
these miRNAs on VEGF expression. Hypoxia-induced CNE cells,
which expressed high levels of VEGF but lacked miR-15b, miR-16,
miR-20a, and miR-20b, were transfected with synthetic miRNA
duplexes of these miRNAs and a set of controls. These include one
positive control, VEGF-siRNA, and four negative controls, miR-
224, mutated miR-16 (miR-16M 59-UAGCCUAACGUAAAUAU-
UGGCG- 39) and miR-20a, miR-20aM 59 -UACGUUGCUUAU-
AGUGCAGGUAG- 39), and a random sequence. MiR-224
was chosen as one of the negative controls because it was
down-regulated during hypoxia but was not predicted to target
VEGF. Transfection with miR-15b, miR-16, miR-20a, and miR-20b,
but not the negative controls, resulted in a 26–51% decrease in
VEGF expression at the protein level 30h after transfection
(Fig. 3A).
We also analyzed the effect of inhibiting endogenous miR-15b,
miR-16, miR-20a, and miR-20b on VEGF expression. Using the
same transfection method, we introduced inhibitors of these
miRNAs into normoxic CNE cells, which express low levels of
VEGF and high levels of endogenous miR-15b, miR-16, miR-20a,
and miR-20b. As we expected, VEGF expression measured by
ELISA increased significantly (Fig. 3B).
To demonstrate a direct interaction between the 39-UTR of
VEGF with candidate miRNAs, we inserted two fragments of the
VEGF 39-UTR predicted to interact with these miRNAs into
a luciferase expression vector to generate luciferase reporter
constructs. Construct I contained a fragment located in nt31–216
of the VEGF 39-UTR, while Construct II contained a fragment in
nt703–944 of the VEGF 39-UTR. Computational predictions
indicated that miR-20a, miR-20b, miR-17-5p, miR-106a, and miR-
106b had binding sites in Construct I. With slightly relaxed criteria
about free energy and conservation, miR-15b, miR-16, miR-17-5p,
miR-20b, and miR-107 have computationally predicted target sites
in Construct II reporters (Table 4). In addition to a random
sequence, miR-29b, miR-150, and miR-383 were employed as
negative controls. All three of these miRNAs have putative binding
sites predicted by one at least of the three algorithms on the
39UTR of VEGF but miR-29b and miR-150 do not have binding
sites on Construct I, and miR-29b and miR-383 have no binding
sites on Construct II. These miRNAs were co-transfected with
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luciferase activity were measured to determine the repressive
effects of these miRNAs. The dual-luciferase activity assays
revealed a repression of 32–68% of luciferase activity compared
to the controls, which showed a repression of less than 15%
(Fig. 4A and B).
Figure 1. Analysis of miRNA binding sites in VEGF. (A) The map of miRNA binding sites in the VEGF 39-UTR in accordance with Table S1. Three
bioinformatics algorithms, RNAhybrid, miRanda, and FindTar, were used to predict miRNA binding sites in the VEGF 39-UTR. A binding site map of the
VEGF 39-UTR was generated with the putative binding sites predicted by at least two bioinformatics algorithms. Subsequently, two miRNA binding
site-condense regions (MBSCR) were uncovered, that is, 160–195nt and 820–860nt MBSCR. (B) A common miRNA binding site located in 160–185nt
shared by 12 miRNAs. (C) The miRNAs that share this common miRNA binding site belong to four different miRNA clusters. (D) The seed region of this
common miRNA binding site is highly conserved among mammals. (E) RNAcofold was used to analyze the secondary structure of the common
miRNA binding site and its flank regions in the VEGF 39-UTR. The common binding site is located in an unstable region with a multi-branching loop-
like RNA structure.
doi:10.1371/journal.pone.0000116.g001
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We have shown that VEGF expression is regulated by multiple
miRNAs. Some miRNAs shared a common binding site, whereas
other miRNAs have their own binding sites in the 39-UTR of
VEGF. To investigate whether different combinations of miRNAs
have different contributions towards VEGF regulation, we per-
formed co-transfection experiments using miR-20a with miR-106b,
which share the same binding site, and miR-20a with miR-361,
which target their own binding sites. Compared to single transfec-
tion with miR-20a, miR-106b,o rmiR-361, co-transfection of
miR-20a with miR-361 exhibited additive repression on VEGF
expression, suggesting a coordinate action of these miRNAs
(Fig. 5A). On the other hand, little difference was observed
between co-transfection of cells with miR-20a and miR-106b. These
results suggest that different miRNA combination patterns can
produce coordinate action, which increases the repressive effect of
miRNAs on VEGF translation, or competitive action, which failed
to generate further repression of VEGF translation. The result of
coordinate action is consistent with Krek’s report [20].
Competitive action among miRNAs can weaken the total
repressive power of an miRNA group. We observed this effect
when miRNAs already validated as true regulators of VEGF were
co-transfected with an miRNA validated as a false positive
regulator. In luciferase reporter Construct II, the inserted
fragment of VEGF 39-UTR contains 1 putative targeting site for
miR-378, located at nt842–864. Four other miRNAs (miR-93, miR-
125a, miR-302d, and miR-373) also targeted this region. The
binding sites of these 5 miRNAs overlapped each other (Fig. 5B).
In luciferase activity assays, a significant repressive effect was
detected when COS-7 cells were co-transfected with Construct II
and miR-93, miR-125a, miR-302d,o rmiR-373, but not miR-378
(Fig. 5C). However, when cells were co-transfected with miR-378
and one of these four miRNAs, the repressive effect of these
miRNAs decreased significantly. In the case of miR-125a, which
shares the same seed region with miR-378, the repressive activity of
miR-125a was abolished completely, suggesting a competitive
interaction between these two miRNAs. Our results also suggest
that some of the false positive miRNAs of a gene may be involved
in miRNA-mediated gene regulation through competitive action.
Table 1. microRNAs down-regulated in DFOM-induced CNE.
......................................................................
miRNA *t test score Fold change
hsa-miR-20b 224.06 58.2761982
hsa-miR-26b 28.49 38.7826763
hsa-miR-15b 27.67 8.185405105
hsa-let-7g 25.95 21.81702918
hsa-miR-224 25.68 3.609585973
hsa-let-7a 25.05 7.70173143
hsa-let-7d 24.55 7.753637176
hsa-miR-16 24.38 11.83290287
hsa-let-7f 24.16 13.21984733
hsa-miR-30b 23.89 8.28519691
hsa-miR-20a 23.80 7.651852239
hsa-let-7c 23.10 6.013923566
hsa-let-7e 22.77 28.37692596
All differentially expressed miRNAs have a q value,0.01 (false-positive rate).
*t test p,0.05.
doi:10.1371/journal.pone.0000116.t001
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Table 2. microRNAs up-regulated in DFOM-induced CNE.
......................................................................
miRNA *t test score Fold change
hsa-miR-155 13.52 4.93
hsa-miR-210 12.12 7.65
hsa-miR-188 8.07 3.48
hsa-miR-181b 7.82 4.35
hsa-miR-30d 4.89 3.33
hsa-miR-151 3.76 3.43
All differentially expressed miRNAs have a q value,0.01 (false-positive rate).
*t test p,0.05.
doi:10.1371/journal.pone.0000116.t002
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Table 3. microRNAs non-differentially expressed in CNE with
or without hypoxia treatment.
......................................................................
miRNA *t test score Fold change
hsa-miR-23b 22.52 2.597
hsa-miR-107 24.40 2.463
hsa-miR-17-5p 23.73 2.217
hsa-miR-103 24.78 1.815
hsa-let-7b 21.09 1.658
hsa-miR-106b 23.57 1.590
hsa-miR-26a 22.47 1.575
hsa-miR-24 24.84 1.563
hsa-let-7i 21.67 1.555
hsa-miR-23a 22.02 1.517
hsa-miR-106a 22.77 1.431
hsa-miR-99a 21.92 1.377
hsa-miR-338 20.09 1.245
hsa-miR-222 20.77 1.107
hsa-miR-27a 20.72 1.098
hsa-miR-31 20.57 1.070
hsa-miR-30c 20.48 1.054
hsa-miR-29a 0.15 1.009
hsa-miR-125b 20.21 1.042
hsa-miR-29b 0.44 1.043
hsa-miR-17-3p 0.78 1.120
hsa-miR-25 0.25 1.125
hsa-miR-193a 0.59 1.211
hsa-miR-29c 1.11 1.253
hsa-miR-100 2.01 1.260
hsa-miR-22 1.57 1.354
hsa-miR-21 1.69 1.367
hsa-miR-221 2.63 1.540
hsa-miR-423 2.91 1.813
hsa-miR-361 3.96 1.844
hsa-miR-30a-5p 4.01 2.103
hsa-miR-92 4.27 2.420
hsa-miR-181a 3.96 2.730
hsa-miR-193b 8.00 2.736
hsa-miR-320 9.51 2.922
doi:10.1371/journal.pone.0000116.t003
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miRNAs.
Co-regulatory effect of miR-15b, miR-16, miR-20a,
and miR-20b on angiogenic factors in CNE cells
When under hypoxia stimulation, VEGF is not the only angio-
genic gene up-regulated, as other angiogenic factors have been
reported to be up-regulated as well [22,23]. Usually, these factors
cooperate together resulting in angiogenesis. We hypothesize that
there must be common regulatory mechanism(s) to modulate
multiple factors involved in angiogenesis. MiRNAs with multiple
targets are able to serve the purpose of co-regulating a group of
functionally related genes, such as multiple angiogenic factors
under strict spacio-temporal conditions.
To test our hypothesis, we identified the angiogenic factors
which are differentially expressed in hypoxia induced CNE cells.
In our previous assays of gene expression profiling in CNE cells, 7
of 40 angiogenesis-related genes, VEGF, c-MET, COX2, uPAR,
PAI1, MAPK7, and Ang were up-regulated when CNE cells were
treated with DFOM. With computational analysis, miR-15b and
miR-16 were predicted to be putative regulatory miRNAs of uPAR,
COX2, and c-MET, in addition to VEGF. MiR-20a and miR-20b
may target c-MET, whereas miR-20b also targets COX2.W e
further investigated whether these angiogenic factors are co-
regulated by these miRNAs, which have been validated as
regulators of VEGF in CNE cells. CNE cells were transfected
with these miRNAs and with reporter vectors, Construct I,
Construct II, and pRL-TK. Western blotting was used to measure
protein expression levels of uPAR, COX2, and c-MET. MiR-15b
and miR-16 down-regulated uPAR, whereas Construct II up-
regulated its expression. It is probable that the fragment of VEGF
39-UTR in Construct II competed with uPAR for endogenous miR-
15b and miR-16 (Fig. 6A). The expression of COX2 was down-
regulated by miR-15b, miR-16, and miR-20b, and c-MET was
down-regulated by all three of these miRNAs plus miR-20a. Both
of these two genes were up-regulated by Construct I and Construct
II (Fig 6B and C). To examine the specificity of these miRNAs in
Figure 2. VEGF and miRNA expression in CNE cells. Cell lysate and culture medium from DFOM-induced CNE cells were collected. RT-PCR (A) and
ELISA (B) assays were performed to determine VEGF expression at the mRNA and protein levels. CNE cells without DFOM treatment were used as
a control. The mirVana
TM miRNA Detection procedure was used to validate miRNA chip data. miR-15b, miR-16, miR-20a, and miR-20b were down-
regulated in hypoxia induced CNE cells (C). I: induced, N: non-induced.
doi:10.1371/journal.pone.0000116.g002
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chose PTN (Pleiotrophin) as a negative control. PTN is an
angiogenic factor known to change during hypoxia, but is not
predicted to be a target of either miR-15b or miR-16. First we
confirmed that PTN expression was up-regulated by the stimula-
tion of hypoxia in CNE cells (Fig. 6D). Then we transfected CNE
cells with miR-15b and miR-16, and found that miR-15b and miR-16
did not have a repressive effect on PTN expression. Furthermore,
we used Construct II to compete with PTN for endogenous miR-
15b and miR-16, but Construct II could not up-regulate PTN
expression. This was expected, as no binding site for miR-15b or
miR-16 was detected by either the miRanda software, RNAhybrid,
or FindTar algorithms in the 39-UTR fragment of PTN. These
data indicate that some of angiogenic factors expressed in CNE
cells were specifically co-regulated by miR-15b, miR-16, miR-20a,
and miR-20b.
DISCUSSION
Possible mechanisms for changes in miRNA levels
during hypoxia in CNE cells
In this investigation, we found that miR-15b, miR-16, miR-20a, and
miR-20b are sharply down-regulated in CNE cells after hypoxia
treatment. The mechanisms for these changes are not clear;
however, we might find some clues from changes in transcription
factors during hypoxia. The tumor suppressor gene p53 might be
one of the critical factors which cause the changes in miRNA levels
during hypoxia. Previous studies indicate that hypoxia could
induce the accumulation of p53 [28,29], and it is possible that the
accumulation of p53 may regulate the expression of several
miRNAs. As an example, miR-15b was down-regulated signifi-
cantly in hypoxic conditions. While no p53-binding sites have been
predicted in the miR-15b promoter [30], it is possible that p53
Figure 3. Validation of the repressive effect of putative miRNA regulators on VEGF expression in CNE cells. (A) Transient overexpression of
miRNAs in hypoxia-induced CNE cells. The effect of miR-15b, miR-16, miR-20a, and miR-20b on VEGF expression was tested in CNE cells by transfection
of the cells with siRNA duplexes homologous in sequence to the miRNAs. ELISA was used to detect VEGF expression levels. The controls consist of
one positive control: VEGF-siRNA (PC), and four negative controls: miR-224, mutated miR-16, and miR-20a (miR-16M, miR-20aM), and a random
sequence (NC). (B) Transfection of miRNA inhibitors in hypoxia non-induced CNE cells. CNE cells were transfected with inhibitors of miR-15b, miR-16,
miR-20a, and miR-20b. siRNA against VEGF was used as positive control. ELISA was used to detect the change in VEGF expression levels after
endogenous miR-15b, miR-16, miR-20a, and miR-20b were inhibited. *, p,0.05; **, p,0.01. NC: negative control; PC: positive control.
doi:10.1371/journal.pone.0000116.g003
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both miR-15b and one of two miR-16 genomic loci, miR-16-2, are
located in the same cluster on chromosome 3 (the miR-15b cluster),
the expression of miR-16 may be regulated by the same mechan-
ism as that of miR-15b. In contrast to miR-15b and miR-16, the
down-regulation of miR-20a and miR-20b may be related to
hypoxia inducible factor-1a (HIF-1a). In response to hypoxia,
HIF-1a becomes stabilized and able to counteract c-Myc function-
ally. In keeping with its antagonism of Myc, HIF-1a down-
regulates c-Myc-activated genes such as hTERT, BRCA1 [31,32],
and might also down-regulate miR-20a and miR-20b, since both
miR-20a and miR-20b may be c-Myc-activated genes. As a member
of the miR-17 cluster located on chromosome 13, the expression of
miR-20a is regulated by c-Myc through direct binding to the
miR-17 cluster locus. Up-regulation of miR-20b, a member of the
miR-106a cluster located on X chromosome, was also consistently
observed in the high c-Myc state and seven putative binding sites
in the vicinity of the miR-106a cluster were also identified even
though no direct binding between c-Myc and these binding sites
has been reported [33]. Taken together, the down-regulation of
miR-15b, miR-16, miR-20a, and miR-20b in CNE cells might be
mediated by the accumulation of p53 or the stabilization of
HIF-1a during hypoxia.
Principles of gene regulation by miRNA
Initial data released by this investigation first reported miRNA-
directed VEGF regulation. Through analysis of this data, we
uncovered some new principles of gene regulation by miRNA and
also further validated principles predicted by others [15,20,21]
using experimental methods. The biological significance of these
principles was also addressed in this investigation.
The first is the coordinate principle. John and Marks [15]
proposed that miRNAs may act cooperatively through multiple
target sites in one gene. Krek’s report proved this principle [20]
and our results further indicate that miRNAs with independent
binding sites in a gene can produce coordinate action, which
increases the repressive effect of miRNAs on translation of this
gene.
The second is the co-regulatory principle. It is a common
phenomenon that groups of functionally related genes act together
to regulate a physiologically related function (e.g. angiogenesis). It
therefore appears as if a common regulatory mechanism controls
the multiple factors involved in these functions. MiRNA with the
ability to target multiple genes could potentially regulate a group
of functionally related genes. In this study, we determined that
some miRNAs identified as VEGF regulators also regulated the
expression of other angiogenic factors. We call this regulatory
pattern a co-regulatory principle, meaning that one or a few
miRNAs can co-regulate a group of functionally related genes.
This is a convenient and efficient regulatory pattern but may cause
unwanted cross-reaction between genes, if an miRNA is expressed
for regulating one gene, but also targets other genes which need
not be repressed under the same conditions. Therefore, there must
be some mechanisms to prevent unwanted cross-reactions.
The third is the principle of differential regulation. As an
miRNA-targeted gene, VEGF might be regulated by many
miRNAs, according to the number of binding sites in its 39-
UTR. However, only some of these miRNAs are involved in
VEGF regulation or VEGF maintenance in CNE cells. The others
might be reserved for the needs of other cells under different
conditions. To ensure that VEGF expression is regulated by
distinct miRNAs in different cells under different conditions, we
analyzed the relationship between VEGF expression and the
miRNA expression profile in five VEGF-expressing cell lines:
CNE, HeLa [34], MCF-7, HL60, and K562 [35]. In these cell
lines, 31–104 miRNAs were detected and 9–31 of those miRNAs
were predicted as putative regulators of VEGF. Through compar-
ison of these five cell lines, we found that not only does each cell
line express different numbers of miRNAs, they also employ
discrete combinations of VEGF-related miRNAs (Table 5). Since
angiogenesis is crucial for a wide variety of physiological and
pathological processes including development, wound healing,
inflammation, and tumor formation, many molecules have been
implicated as positive regulators of angiogenesis. Being a pivotal
factor, VEGF expression is complex and needs to be well regulated
[22,23]. Various miRNA binding sites provide a number of
choices which not only meet different needs under various
processes but also avoid unwanted cross-reactions. We call this
pattern differential regulation, which means that a gene with
multiple binding sites for a number of miRNAs can be regulated
by discrete miRNAs in differing cells under different conditions.
However, the pattern of differential regulation may not be enough
to prevent unwanted cross-reactions between genes, since some
miRNAs have too many target genes.
Competitive action was recognized as the final principle of gene
regulation by miRNAs, and it can be seen when multiple miRNAs
compete with each other for a common binding site (called a multi-
miRNA binding site) or a functional miRNA competes with a false
positive miRNA for the same binding site. The biological role of
competitive action is not very clear. It might be related to
prevention of unwanted cross-reactions between genes. In this
investigation, we found a multi-miRNA binding site located in
nt162–185 of the VEGF 39-UTR, which functioned as a specially
designed ruse for the prevention of unwanted cross-reactions
between miRNA-targeting genes. This binding site is shared by 12
different miRNAs, according to the bioinformatics prediction, but
only miR-17-5p, miR-20a, miR-20b, miR-106a, and miR-106b were
detected in DFOM-untreated CNE cells. Among these 5 miRNAs,
Table 4. miRNA binding sites at fragments of the VEGF 39-UTR
in report vector Construct I or II.
......................................................................
name of miRNA Free energy (DG) location
Construct 1
hsa-miR-17-5p 227.5 165–184*
hsa-miR-20a 225.9 166–184*
hsa-miR-20b 229.3 166-184*
hsa-miR-106a 225.9 162–184*
hsa-miR-106b 224.6 166–184*
Construct 2
hsa-miR-15b 220.2 798–822*
hsa-miR-16 222.7 793–822*
hsa-miR-17-5p 218.8 776–799*
hsa-miR-20b 215.0 777–799*
hsa-miR-93 218.2 826–848
hsa-miR-107 225.6 801–821*
hsa-miR-125a 215.1 843–864
hsa-miR-302d 220.2 825–848
hsa-miR-372 227.6 821–848
hsa-miR-373 225.7 825–848
hsa-miR-378 229.0 842–864
*endogenous miRNAs
doi:10.1371/journal.pone.0000116.t004
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PLoS ONE | www.plosone.org 7 December 2006 | Issue 1 | e116miR-20a and miR-20b were validated as regulatory miRNAs in
hypoxia-induced VEGF expression, whereas the other three could
be expressed for the regulation of other genes without over-
repressing VEGF expression due to competitive action. Thus, the
unwanted cross-reaction of VEGF with other genes could be
prevented. In some circumstances, if VEGF expression needs no
repression, but some regulatory miRNAs of VEGF are expressed
for regulation of other genes, the unwanted cross-reaction of
VEGF can be decreased through the expression of false positive
miRNAs to compete with the functionally effective miRNAs. The
competitive principle, differential regulation, multi-miRNA bind-
ing sites, and false positive miRNAs might be useful strategies to
avoid unwanted cross actions between targeting genes of miRNAs
with multiple targets. The patterns of miRNA-directed VEGF
regulation demonstrate several principles of miRNA-mediated
gene regulation, and these principles will be helpful for us to
understand the highly complex pattern of gene regulation by
miRNAs.
Some concerns about negative control miRNAs
To test the specificity of prediction of miRNA target sites, we first
did experiments with a luciferase activity assay to test: a) the effects
of miR-106a and miR-106b on Construct II; and b) the effects of
miR-15b and miR-16 on Construct I. We found that all of these
miRNAs showed repression of 20–27% of luciferase activity. The
criteria that we used to predict miRNA targets of VEGF in this
investigation are: only the binding sites predicted by two of the
three bioinformatics algorithms, miRanda software, RNAhybrid,
and FindTar algorithm, were selected as putative binding sites for
miRNA in the VEGF 39-UTR. According to the criteria, no
binding sites for miR-15b and miR-16 on Construct I and miR-106a
and miR-106b on Construct II were found. However, the result of
the luciferase activity assay suggests that this is a false negtive
prediction. Combinative use of more than one computational
algorithm in the prediction of miRNA binding sites could decrease
the false positive rate, but it might increase the false negtive rate
Figure 4. Luciferase activity assay. Luciferase reporter constructs were generated through placing fragments of 185 bp (Construct I, sequence from
nt31–216 of the VEGF 39-UTR) and 241 bp (Construct II, sequence from nt703–944 of the VEGF 39-UTR) at the 39 end of luciferase gene in pRL-TK.
COS-7 cells were co-transfected with a luciferase reporter vector and an miRNA which has a putative binding site in either Construct I (A) or Construct
II (B). Luciferase activity was measured to determine the effects of these miRNAs on luciferase translation. In addition to a random sequence (NC),
miR-29, miR-150, and miR-383 which have putative binding sites in the 39-UTR of VEGF but not on Construct I or II, as predicted by all of the
algorithms, were employed as negative controls. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0000116.g004
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good. When the prediction was carried out with miRanda
software, RNAhybrid, and FindTar algorithms separately, binding
sites for miR-15b and miR-16 on Construct I and miR-106a and
miR-106b on Construct II would be detected by one of these
algorithms. We therefore chose miR-29b, miR-150, and miR-383,
which have putative binding sites on the 39-UTR of VEGF but do
not have putative binding sites on Construct I or II, as predicted
Figure 5. Effects of different combinations of miRNAs on VEGF expression. (A) CNE cells were transfected or co-transfected with miR-20a and miR-
106b, which share the same binding site, or with miR-20a and miR-361, which target different binding sites. An unrelated random sequence was used
as a negative control (NC). A specific sequence targeting VEGF (functioning as siRNA) was used as a positive control (PC). Culture medium was
collected 30h after transfection. Repression of VEGF expression was detected by ELISA. (B) miRNA binding site locations of miR-378, miR-125a, miR-93,
miR-302d, and miR-373 in the VEGF 39-UTR fragment of Construct II. (C) COS-7 cells were co-transfected with (1) Construct II and miR-378, miR-125a,
miR-93, miR-302d,o rmiR-373; (2) Construct II and miR-378 plus either miR-125a, miR-93, miR-302d,o rmiR-373. Luciferase activity was measured to
investigate the effects of different combinations of miRNAs. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0000116.g005
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PLoS ONE | www.plosone.org 9 December 2006 | Issue 1 | e116by all of the three algorithms, to test the specificity. As we
expected, miR-29b, miR-150, and miR-383 did not show repressive
effects on Construct I or II. Our results suggest that it is important
to confirm that an miRNA is not a potential regulatory miRNA of
a specific gene by using different bioinformatics algorithms before
using the miRNA as a negative control.
MATERIALS AND METHODS
Cell culture and hypoxia inducement
CNE cells, a human nasopharyngeal carcinoma cell line, were
obtained from Kunming Cell Bank (Kunming, China) and
maintained in RPMI 1640 medium containing 10% FBS at
37uC with 5% CO2. Hypoxia inducement was carried out with
DFOM (Sigma-Aldrich Co., MO, USA) at a final concentration of
130 uM and cells without DFOM treatment were used as control.
After 20 hours of DFOM treatment, the cells were harvested and
total RNA was isolated with TRIzol Reagent (Invitrogen Corp.
CA) according to the manufacturer’s protocol.
RNA preparation, miRNA microarray experiments,
and miRNA detection
Total RNA samples were sent to CapitalBio (CapitalBio Corp.,
Beijing, China) for miRNA microarray experiments. Procedures
were performed as described in detail on the website of CapitalBio
(http://www.capitalbio.com). Briefly, 50–100 mg of total RNA
were used to extract miRNA using an miRNA Isolation Kit
(Ambion Inc. Texas). Fluorescein-labeled miRNA [36] were used
for hybridization on each miRNA microarray chip containing 509
probes in triplicate, corresponding to 435 human (including 122
predicted miRNAs), 261 mouse, and 196 rat miRNAs found in
the miRNA Registry (http://microrna.sanger.ac.uk/sequences/;
accessed Oct. 2005) or collected from a published paper [37]. Raw
data were normalized and analyzed in GenePix Pro 4.0 software
(Axon Instruments, PA, USA). Expression data were median-
centered by using the global median normalization of the
BIOCONDUCTOR package (http://www.bioconductor.org).
Statistical comparisons were done with SAM software (SAM
version 2.1, http://www-stat.stanford.edu/,tibs/SAM/index.
html) [25,26]. The microarray data were confirmed through an
miRNA detection experiment with the mirVana
TM miRNA
detection kit (Ambion Inc. Texas).
Cell transfection with miRNAs or miRNA inhibitors
SiRNA duplexes homologous in sequence to miRNA and their
inhibitors were synthesized and purified by Shanghai Gene-
Pharma Co. (Shanghai, China). The sequences of these inhibitors
are the exact antisense copy of the mature miRNAs and all the
nucleotides in the inhibitors contain 29-OMe modifications at each
base. A VEGF siRNA which targets mRNA sequence 59-GGAG-
UACCCUGAUGAGAUC-39 (nt189–207) [38] was used as a
positive control (PC). SiRNA duplexes with non-specific sequences
were used as a negative control (NC).
Figure 6. Co-regulation of miRNAs to angiogenic factors. CNE cells were induced with or without DFOM (6–1), transfected with miR-15b, miR-16,
miR-20a,o rmiR-20b (6–2) and transfected with Construct I or Construct II (6–3). Cell lysate was collected, and the expression of angiogenic factors
uPAR (A), COX2 (B), c-MET (C), and PTN (D) were determined by Western Blotting.
doi:10.1371/journal.pone.0000116.g006
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cells using the transfection protocol recommended by Invitrogen. In
brief, CNE cells were seeded into 96 or 24 well plates one day prior to
transfection. When the cells reached 50–70% confluence, miRNA
duplexes or their inhibitors were transfected into the cells at
a concentration of 4 or 6 pmol/well for the 96 well plates, and 20
or 30 pmol/well for the 24 well plates, using the Lipofectamine 2000
reagent (Invitrogen Corp. CA, USA). Hypoxia induction was carried
out using the method described before. The same amount of negative
control RNA duplexes and VEGF siRNA were also transfected. The
celllysate and culture medium were collected 30 hr post-transfection.
Assay of luciferase activity
To perform luciferase activity assays, VEGF 39-UTR (nt163–184)
and its flank sequence was PCR-amplified using two primers,
59-CGTTCTAGAGTTTCGGGA ACCAGATCTC-39 and 59-
AACACTAGTAATGCTTCCGCCGGAGT-39. Two copies of
the target sequence were cloned downstream of the stop codon in
pRL-TK (Promega Corp. WI, USA). The other sequence which
contains multiple binding sites in VEGF 39-UTR (nt700–850) was
also amplified using two primers, 59- TCTTCTAGACAGGTCA-
GACGGACAG-39 and 59-ACAACTAGTCTCTTCTCTTCG-
CCGG-39, and two copies of the target sequence were cloned
downstream of the stop codon in pRL-TK. We pre-plated COS-7
or CNE cells 24 h prior to transfection in 24-well tissue culture
plates. The next day COS-7 or CNE cells were transfected with
100 or 400 ng of pRL-TK (Rr-luc) and 5 or 100 ng of pGL3
control vector (Pp-luc, from Promega Corp. WI, USA). For the co-
transfection of miRNAs or their inhibitors with reporter vectors,
20 nM of each miRNA duplex or 30 nM of each inhibitor was
transfected using Lipofectamine 2000. Cell lysate was collected
and assayed 30 h after transfection. Firefly and Renilla luciferase
activities were measured using a Dual Luciferase Reporter Assay
System (Promega Corp. WI, USA) and each transfected well was
assayed in triplicate as described [14].
ELISA assays
The culture medium of CNE cells was recovered for ELISA assays
using VEGF ELISA from R & D systems (Minneapolis, MN) and
a GENios ELISA plate reader (TECAN, Austria). All experiments
were repeated four times.
Western blots
Cell supernatant or cell lysate was subjected to SDS-PAGE and
transferred to a nitrocellulose membrane. Protein expression was
analyzed by Western blotting with primary antibodies against
uPAR, COX2, c-MET, and PTN (Santa Cruz, California) and
then incubated with a secondary antibody. After washing, the
bound antibody was visualized with an ECL kit (Amersham
Pharmacia Biotech, NJ, USA) as described previously [39].
RT-PCR
Total RNA was isolated with TRIzol Reagent (Invitrogen,
Gaithersburg, MD) according to the manufacturer’s protocol.
RT-PCR was performed with the total RNA using TaKaRa one
step RNA PCR kit (TaKaRa Bio Inc, Japan). The VEGF
expression level was detected with a pair of primers, forward: 59-
GAGGGCAGAATCATCACGAA-39; reverse: 59-GGGAACG-
CTCCAGGACTTAT-39. The gene expression level of VEGF
was normalized against a housekeeping gene, glyceraldehyde-3-
phosphate dehydrogenase (GADPH).
Bioinformatics
miRNA target site prediction of VEGF and other angiogenic factors
was performed by using miRanda software [12] (http://www.
Table 5. miRNAs which putatively target VEGF and are
expressed in CNE, HeLa, MCF7, HL60, and K562.
......................................................................
miRNAs CNE HeLa MCF7 HL60 K562
hsa-let-7b ++ no no no
hsa-miR-16 + no ++ +
hsa-miR-17-5p + n/a ++ +
hsa-miR-18a no n/a ++ +
hsa-miR-20a + n/a no no no
hsa-miR-20b + n/a n/a n/a n/a
hsa-miR-27a ++ ++ +
hsa-miR-30a-3p no n/a ++ +
hsa-miR-34a no ++ + +
hsa-miR-93 no ++ + +
hsa-miR-106a ++ no no no
hsa-miR-106b + no ++ +
hsa-miR-107 + no ++ +
hsa-miR-124a no + no + no
hsa-miR-125a no ++ no +
hsa-miR-127 no no ++ +
hsa-miR-130b no no no ++
hsa-miR-134 no no + no +
hsa-miR-135b no n/a no no +
hsa-miR-150 no no ++ +
hsa-miR-182 no no ++ +
hsa-miR-189 no + n/a n/a n/a
hsa-miR-193a + n/a no no +
hsa-miR-195 no no ++ +
hsa-miR-196a no n/a ++ +
hsa-miR-196b no n/a ++ +
hsa-miR-199a no ++ + +
hsa-miR-210 + no ++ +
hsa-miR-214 no no ++ +
hsa-miR-302d no n/a no + no
hsa-miR-320 + no ++ +
hsa-miR-330 no n/a + no +
hsa-miR-331 no n/a ++ +
hsa-miR-339 no n/a ++ +
hsa-miR-346 no n/a ++ +
hsa-miR-361 + n/a no no no
hsa-miR-373 no n/a no ++
hsa-miR-378 no n/a no ++
hsa-miR-422b no n/a ++ +
hsa-miR-425 no n/a no + no
V-miRNAs/T-miRNAs 13/54 9/31 26/78 29/102 31/104
‘‘+’’ indicates those miRNAs which are expressed in a specific cell line and have
predictive targets in the 39 untranslated region of VEGF; ‘‘2’’ indicates those
miRNAs which are not expressed in a specific cell line; ‘‘n/a’’ indicates that the
miRNA is not within the detection range in certain experimental approaches;
‘‘V-miRNAs’’ means miRNAs targeting VEGF; T-miRNAs means total miRNAs
which are expressed in the cell lines.
doi:10.1371/journal.pone.0000116.t005
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PLoS ONE | www.plosone.org 11 December 2006 | Issue 1 | e116microrna.org/miranda_new.html), RNAhybrid [19] (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/webservice.html), and
FindTar algorithm, a bioinformatics approach designed by us.
MiRanda was used for the primary screening of miRNA target sites
with cut-off values for free energy (DG),214 kcal/mole and
scores.70, and the FindTar algorithm for secondary screening with
ac r i t e r i ao f( DG),220 kcal/mole, and high conservation among
mammals.The program was run with a temperaturesettingat37uC.
39-UTR Datasets and MicroRNA Datasets 39 untrans-
lational region (39-UTR) sequences of VEGF from human (Homo
sapiens), mouse (Mus musculus), rat (Rattus norvegicus), chimpanzee
(Pan troglodytes), and Cow (Bos taurus) were retrieved using Ensembl
Data base (http://www.ensembl.org). Human miRNA sequences
of the RFAM miRNA registry [40] were downloaded from the
miRBase website (http://microrna.sanger.ac.uk/sequences/index.
shtml).
The design of FindTar algorithm It was recognized that
the nucleus or seed, typically a perfectly Watson-Crick–base-
paired stretch of 7 nt starting at either the first or the second base
of the microRNA (counted from the 59 end), was the most critical
for target recognition [13,14,17]. In the design of the FindTar
algorithm, we started with experimental results from other groups
[14,18], and used a slightly relaxed seed criterion to search the
mRNA sequences for a binding site, so that more potential
miRNA targets could be included in the primary screening. Our
seed criterion was defined as a perfectly Watson-Crick–base-
paired stretch of 6 nt starting at the first, second, or third base of
the miRNA, but one G-U wobble in the seed would be tolerable.
After the seed regions were identified, we predicted the secondary
structure and minimum free energy of the possible miRNA:miRBS
(miRBS: miRNA binding site) using RNAcofold software (Vienna
RNA Package 1.5 beta version, http://www.tbi.univie.ac.at/
,ivo/RNA/). RNAcofold was also incorporated into the
FindTar algorithm. Sequences of miRNA binding sites in
mRNA, and a given miRNA, were input for precisely predicting
the RNA secondary structures of the miRNA/miRBS duplexes
and calculating minimum free energy (DG) of the whole miRNA/
miRBS duplex.
SUPPORTING INFORMATION
Table S1 RNAhybrid, miRanda, and FindTar were used to
predict potential binding sites of each human miRNA. The sites
found by two or all of these three software were chosen as putative
binding sites for miRNAs (all these sites were predicted by
FindTar). Free energy is calculated by RNAcofold.
Found at: doi:10.1371/journal.pone.0000116.s001 (0.14 MB
DOC)
Figure S1 Image of miRNA microarray. miRNA array analysis
was performed with mRNA samples from hypoxia-induced CNE
cells (A and B) and non-induced CNE cells (C and D). An miRNA
microarray chip containing 509 probes in triplicate was used in the
analysis.
Found at: doi:10.1371/journal.pone.0000116.s002 (6.39 MB TIF)
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